Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication

BACKGROUND Left atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patients with a thrombotic event despite OAT are at high risk for recurrence and may also bene fit from LAAO. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores: Aarnink, EW, Maarse, M, Fierro, N, Mazzone, P, Beneduce, A, Tondo, C, Gasperetti, A, Pracon, R, Demkow, M, Zielinski, K, de Backer, O, Korsholm, K, Nielsen-Kudsk, JE, Estévez-Loureiro, R, Caneiro-Queija, B, Benito-González, T, de Prado, AP, Nombela-Franco, L, Salinas, P, Holmes, D, Almakadma, AH, Berti, S, Romeo, MR, Millan, X, Arzamendi, D, Alla, VM, Agarwal, H, Eitel, I, Paitazoglou, C, Freixa, X, Cepas-Guillén, P, Chothia, R, Badejoko, SO, Spoon, DB, Maddux, JT, El-Chami, M, Ram, P, Branca, L, Adamo, M, Suradi, HS, Peper, J, van Dijk, VF, Rensing, BJWM, Swaans, MJ, Vireca, E, Bergmann, MW, Boersma, LVA
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p19233
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19233
https://ddd.uab.cat/record/324020
Access Level:acceso abierto
Palabra clave:KEY WORDS anticoagulation failure
atrial fi brillation
ischemic stroke
left atrial appendage occlusion
id ES_e17c0e37751691e5cb9fea97a1880d21
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p19233
network_acronym_str ES
network_name_str España
repository_id_str
spelling Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation ContraindicationAarnink, EWMaarse, MFierro, NMazzone, PBeneduce, ATondo, CGasperetti, APracon, RDemkow, MZielinski, Kde Backer, OKorsholm, KNielsen-Kudsk, JEEstévez-Loureiro, RCaneiro-Queija, BBenito-González, Tde Prado, APNombela-Franco, LSalinas, PHolmes, DAlmakadma, AHBerti, SRomeo, MRMillan, XArzamendi, DAlla, VMAgarwal, HEitel, IPaitazoglou, CFreixa, XCepas-Guillén, PChothia, RBadejoko, SOSpoon, DBMaddux, JTEl-Chami, MRam, PBranca, LAdamo, MSuradi, HSPeper, Jvan Dijk, VFRensing, BJWMSwaans, MJVireca, EBergmann, MWBoersma, LVAKEY WORDS anticoagulation failureatrial fi brillationischemic strokeleft atrial appendage occlusionBACKGROUND Left atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patients with a thrombotic event despite OAT are at high risk for recurrence and may also bene fit from LAAO. OBJECTIVES This study sought to investigate the ef ficacy of LAAO in AF patients with a thrombotic event on OAT compared to: 1) LAAO in AF patients with a contraindication for OAT; and 2) historical data. METHODS The international LAAO after stroke despite oral anticoagulation (STR-OAC LAAO) collaboration included patients who underwent LAAO because of thrombotic events on OAT. This cohort underwent propensity score matching and was compared to the EWOLUTION (Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving WATCHMAN Left Atrial Appendage Closure Technology) registry, which represents patients who underwent LAAO because of OAT contraindications. The primary outcome was ischemic stroke. Event rates were compared between cohorts and with historical data without OAT, yielding relative risk reductions based on risk scores. RESULTS Analysis of 438 matched pairs revealed no signi ficant difference in the ischemic stroke rate between the STR-OAC LAAO and EWOLUTION cohorts (2.5% vs 1.9%; HR: 1.37; 95% CI: 0.72-2.61). STR-OAC LAAO patients exhibited a higher thromboembolic risk (HR: 1.71; 95% CI: 1.04-2.83) but lower bleeding risk (HR: 0.39; 95% CI: 0.18-0.88) compared to EWOLUTION patients. The mortality rate was slightly higher in EWOLUTION (4.3% vs 6.9%; log -rank P 1 / 4 0.028). Relative risk reductions for ischemic stroke were 70% and 78% in STR-OAC LAAO and EWOLUTION, respectively, compared to historical data without OAT. CONCLUSIONS LAAO in patients with a thrombotic event on OAT demonstrated comparable stroke rates to the contraindicated population in EWOLUTION. The thromboembolic event rate was higher and the bleeding rate lower, reftecting the intrinsically different risk pro file of both populations. Until randomized trials are available, LAAO may considered in patients with an ischemic event on OAT. (J Am Coll Cardiol Intv 2024;17:1311 -1321) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).ELSEVIER SCIENCE INC2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19233https://ddd.uab.cat/record/324020JACC-Cardiovascular InterventionsISSN: 19368798ISSNe: 18767605reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p192332026-06-14T12:41:47Z
dc.title.none.fl_str_mv Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
title Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
spellingShingle Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
Aarnink, EW
KEY WORDS anticoagulation failure
atrial fi brillation
ischemic stroke
left atrial appendage occlusion
title_short Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
title_full Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
title_fullStr Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
title_full_unstemmed Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
title_sort Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication
dc.creator.none.fl_str_mv Aarnink, EW
Maarse, M
Fierro, N
Mazzone, P
Beneduce, A
Tondo, C
Gasperetti, A
Pracon, R
Demkow, M
Zielinski, K
de Backer, O
Korsholm, K
Nielsen-Kudsk, JE
Estévez-Loureiro, R
Caneiro-Queija, B
Benito-González, T
de Prado, AP
Nombela-Franco, L
Salinas, P
Holmes, D
Almakadma, AH
Berti, S
Romeo, MR
Millan, X
Arzamendi, D
Alla, VM
Agarwal, H
Eitel, I
Paitazoglou, C
Freixa, X
Cepas-Guillén, P
Chothia, R
Badejoko, SO
Spoon, DB
Maddux, JT
El-Chami, M
Ram, P
Branca, L
Adamo, M
Suradi, HS
Peper, J
van Dijk, VF
Rensing, BJWM
Swaans, MJ
Vireca, E
Bergmann, MW
Boersma, LVA
author Aarnink, EW
author_facet Aarnink, EW
Maarse, M
Fierro, N
Mazzone, P
Beneduce, A
Tondo, C
Gasperetti, A
Pracon, R
Demkow, M
Zielinski, K
de Backer, O
Korsholm, K
Nielsen-Kudsk, JE
Estévez-Loureiro, R
Caneiro-Queija, B
Benito-González, T
de Prado, AP
Nombela-Franco, L
Salinas, P
Holmes, D
Almakadma, AH
Berti, S
Romeo, MR
Millan, X
Arzamendi, D
Alla, VM
Agarwal, H
Eitel, I
Paitazoglou, C
Freixa, X
Cepas-Guillén, P
Chothia, R
Badejoko, SO
Spoon, DB
Maddux, JT
El-Chami, M
Ram, P
Branca, L
Adamo, M
Suradi, HS
Peper, J
van Dijk, VF
Rensing, BJWM
Swaans, MJ
Vireca, E
Bergmann, MW
Boersma, LVA
author_role author
author2 Maarse, M
Fierro, N
Mazzone, P
Beneduce, A
Tondo, C
Gasperetti, A
Pracon, R
Demkow, M
Zielinski, K
de Backer, O
Korsholm, K
Nielsen-Kudsk, JE
Estévez-Loureiro, R
Caneiro-Queija, B
Benito-González, T
de Prado, AP
Nombela-Franco, L
Salinas, P
Holmes, D
Almakadma, AH
Berti, S
Romeo, MR
Millan, X
Arzamendi, D
Alla, VM
Agarwal, H
Eitel, I
Paitazoglou, C
Freixa, X
Cepas-Guillén, P
Chothia, R
Badejoko, SO
Spoon, DB
Maddux, JT
El-Chami, M
Ram, P
Branca, L
Adamo, M
Suradi, HS
Peper, J
van Dijk, VF
Rensing, BJWM
Swaans, MJ
Vireca, E
Bergmann, MW
Boersma, LVA
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv KEY WORDS anticoagulation failure
atrial fi brillation
ischemic stroke
left atrial appendage occlusion
topic KEY WORDS anticoagulation failure
atrial fi brillation
ischemic stroke
left atrial appendage occlusion
description BACKGROUND Left atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patients with a thrombotic event despite OAT are at high risk for recurrence and may also bene fit from LAAO. OBJECTIVES This study sought to investigate the ef ficacy of LAAO in AF patients with a thrombotic event on OAT compared to: 1) LAAO in AF patients with a contraindication for OAT; and 2) historical data. METHODS The international LAAO after stroke despite oral anticoagulation (STR-OAC LAAO) collaboration included patients who underwent LAAO because of thrombotic events on OAT. This cohort underwent propensity score matching and was compared to the EWOLUTION (Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving WATCHMAN Left Atrial Appendage Closure Technology) registry, which represents patients who underwent LAAO because of OAT contraindications. The primary outcome was ischemic stroke. Event rates were compared between cohorts and with historical data without OAT, yielding relative risk reductions based on risk scores. RESULTS Analysis of 438 matched pairs revealed no signi ficant difference in the ischemic stroke rate between the STR-OAC LAAO and EWOLUTION cohorts (2.5% vs 1.9%; HR: 1.37; 95% CI: 0.72-2.61). STR-OAC LAAO patients exhibited a higher thromboembolic risk (HR: 1.71; 95% CI: 1.04-2.83) but lower bleeding risk (HR: 0.39; 95% CI: 0.18-0.88) compared to EWOLUTION patients. The mortality rate was slightly higher in EWOLUTION (4.3% vs 6.9%; log -rank P 1 / 4 0.028). Relative risk reductions for ischemic stroke were 70% and 78% in STR-OAC LAAO and EWOLUTION, respectively, compared to historical data without OAT. CONCLUSIONS LAAO in patients with a thrombotic event on OAT demonstrated comparable stroke rates to the contraindicated population in EWOLUTION. The thromboembolic event rate was higher and the bleeding rate lower, reftecting the intrinsically different risk pro file of both populations. Until randomized trials are available, LAAO may considered in patients with an ischemic event on OAT. (J Am Coll Cardiol Intv 2024;17:1311 -1321) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19233
https://ddd.uab.cat/record/324020
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19233
https://ddd.uab.cat/record/324020
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCIENCE INC
publisher.none.fl_str_mv ELSEVIER SCIENCE INC
dc.source.none.fl_str_mv JACC-Cardiovascular Interventions
ISSN: 19368798
ISSNe: 18767605
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422296944345088
score 15,81155